Iscar for Supplemental Care in Stage IV Lung Cancer
Status:
Completed
Trial end date:
2004-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study it to determine whether supplemental treatment with Iscar improves
immune function and quality of life among Stage IV non-small cell lung carcinoma patients
receiving conventional chemotherapy. Iscar is an herbal medicine made from the total plant
extract of mistletoe. this preparation is already in use in Europe and its use in the US is
likely to increase as cancer patients continue to seek alternative therapies.
Phase:
Phase 2
Details
Lead Sponsor:
National Center for Complementary and Integrative Health (NCCIH)